AstralBio

Curated by Signal

Developer of antibodies for cardiometabolic and immune-mediated disease

Overview

Developer of antibodies for cardiometabolic and immune-mediated diseases. It offers AI-driven technology to accelerate the discovery of biological drugs to develop treatments for obesity and other cardiometabolic diseases.

Key facts

Founded: 2023
Headquarters: Boston, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

1 product or service: Sign up to view

Contact

Primary office: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

NeuroEM
Head worn device to prevent and treat Alzheimer's Disease with electromagnetic waves
Life Sciences TechnologyPhoenix, United States
MiRTLE Medical
Provider of MRI-compatible 12-lead ECG monitoring system
Life Sciences TechnologyNorth Andover, United States
GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer
Life Sciences TechnologyMenlo Park, United States

About AstralBio

What does AstralBio do?

Developer of antibodies for cardiometabolic and immune-mediated diseases.

Where is AstralBio headquartered?

AstralBio is headquartered in Boston, United States.

When was AstralBio founded?

AstralBio was founded in 2023.

Which sector is AstralBio in?

AstralBio operates in Life Sciences Technology.

Who are AstralBio's competitors?

Companies similar to AstralBio include NeuroEM, MiRTLE Medical, and GRAIL.